Form 4: Revolution Medicines' General Counsel Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Jeff Cislini, General Counsel of Revolution Medicines, sold 1,599 shares of common stock on December 16, 2024, to cover tax obligations related to vesting restricted stock units.
Summary
- On December 16, 2024, Jeff Cislini, the General Counsel of Revolution Medicines, sold 1,599 shares of the company's common stock.
- The sale was executed at a price of $45.4038 per share.
- This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on May 31, 2023, to cover tax withholding obligations upon the vesting of restricted stock units (RSUs).
- Following the transaction, Cislini beneficially owns 41,628 shares, which includes 147 shares acquired under the Employee Stock Purchase Plan on November 30, 2024, and 36,204 RSUs.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (share sale for tax obligations) by an insider, which is neither particularly positive nor negative.
Industry Context
Sales of shares by company insiders are a common occurrence, often related to tax obligations or diversification strategies. Rule 10b5-1 plans are frequently used to allow insiders to sell shares at predetermined times to avoid accusations of insider trading.
Key Dates
| Date | Description |
|---|---|
| May 31, 2023 | Date of adoption of Rule 10b5-1 trading plan. |
| July 15, 2023 | RSUs vesting after this date are subject to the trading plan. |
| November 30, 2024 | Date of acquisition of 147 shares under the Employee Stock Purchase Plan. |
| December 16, 2024 | Date of the share sale transaction. |
| December 18, 2024 | Date of signature of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.